LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Inicio・Lista de Acciones・Novartis AG

Novartis AG

Cerrado

109.31 0.77

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

109.13

Máximo

109.78

Métricas clave
By Trading Economics
Ingresos	501M 3.2B
Ventas	1.1B 13B
P/B Media del Sector	23.52 104.138
BPA	1.57
Margen de beneficio	24.21
EBITDA	950M 5.6B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+13.06 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	3.5B 224B
Apertura anterior	108.54
Cierre anterior	109.31

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

107.935 / 113.93 Soporte y Resistencia

Novartis AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 oct 2024, 06:31 UTC

Ganancias

Novartis Lifts Guidance Again After Key Drugs Help Profit, Sales Beat Market Views

28 oct 2024, 12:14 UTC

Principales Movimientos del Mercado

Monte Rosa Therapeutics Shares Soar on Novartis Team-Up

26 ago 2024, 09:47 UTC

Adquisiciones, fusiones, absorciones

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

29 oct 2024, 18:15 UTC

Principales Noticias

Novartis Stock Dives on $800 Million Write-Down -- Heard on the Street -- WSJ

29 oct 2024, 15:40 UTC

Ganancias

Novartis Sacrifices A Flat Base On Lagging Sales Of Its Biggest Moneymaker -- IBD

29 oct 2024, 11:39 UTC

Ganancias

Novartis Reports Q3 Momentum, But Shares Lose Support -- IBD

29 oct 2024, 09:51 UTC

Charlas de Mercado

Ganancias

Novartis Key Heart Drug's Miss Stands Out in 3Q Results -- Market Talk

29 oct 2024, 09:03 UTC

Acciones populares

Stocks to Watch Tuesday: McDonald's, Ford, Trump Media -- WSJ

29 oct 2024, 08:11 UTC

Charlas de Mercado

Ganancias

Novartis's Midterm Targets Look Achievable -- Market Talk

29 oct 2024, 06:05 UTC

Ganancias

Novartis 3Q Net Pft $3.19B

29 oct 2024, 06:04 UTC

Ganancias

Novartis 3Q Adj EPS $2.06

29 oct 2024, 06:03 UTC

Ganancias

Novartis 3Q EPS $1.58

29 oct 2024, 06:03 UTC

Ganancias

Novartis 3Q Oper Pft $3.63B

29 oct 2024, 06:03 UTC

Ganancias

Novartis Had Seen 2024 Sales to Grow In High-Single to Low-Double-Digits

29 oct 2024, 06:03 UTC

Ganancias

Novartis Expects 2024 Sales to Grow Low-Double-Digit

29 oct 2024, 06:03 UTC

Ganancias

Novartis Had Seen 2024 Core Operating Profit to Grow From a Mid to High Teens Range

29 oct 2024, 06:03 UTC

Ganancias

Novartis Expects 2024 Core Operating Profit to Grow High Teens

29 oct 2024, 06:02 UTC

Ganancias

Novartis Sees 2024 Guidance At Top End Of Previous Range

29 oct 2024, 06:01 UTC

Ganancias

Analysts Had Novartis 3Q Core Operating Profit at $4.87B

29 oct 2024, 06:01 UTC

Ganancias

Novartis 3Q Core Operating Profit $5.145B

29 oct 2024, 06:00 UTC

Ganancias

Analysts Had Novartis 3Q Sales at $12.62B

29 oct 2024, 06:00 UTC

Ganancias

Novartis 3Q Sales $12.82B

29 oct 2024, 06:00 UTC

Ganancias

Novartis AG 3Q Adj EPS $2.06

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept 2024, 14:07 UTC

Charlas de Mercado

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19 ago 2024, 13:36 UTC

Charlas de Mercado

Novartis Well on Track to Achieve Guidance -- Market Talk

14 ago 2024, 09:02 UTC

Charlas de Mercado

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18 jul 2024, 11:55 UTC

Ganancias

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18 jul 2024, 09:40 UTC

Charlas de Mercado

Ganancias

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18 jul 2024, 08:45 UTC

Charlas de Mercado

Ganancias

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

Comparación entre iguales

Cambio de precio

Novartis AG Esperado

Precio Objetivo

By TipRanks

13.06% repunte

Estimación a 12 meses

Media 123.63 USD 13.06%

Máximo 130 USD

Mínimo 120 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Novartis AG Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

107.935 / 113.93Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.